Gates Ventures

What Gates Ventures does

Gates Ventures is the personal investment office of Bill Gates, managing his private investments, venture activities, and science-focused initiatives outside the Gates Foundation. The firm, formerly known as bgC3, was founded in 2008 and is headquartered in Kirkland, Washington, with 51-100 employees. Gates Ventures operates as a private investment and initiative-coordination vehicle rather than a product company, channeling capital into global health, energy innovation, and most prominently Alzheimer's disease research.

The firm's most material technology asset is the AD Workbench, a cloud-based research environment developed through the Alzheimer's Disease Data Initiative (ADDI). AD Workbench connects hundreds of dementia research datasets globally, including data from the GAP Bio-Hermes-002 study and the SpeechDx multinational observational study, the latter generating a longitudinal speech dataset licensed to Siemens Healthineers and Callyope for AI-driven Alzheimer's detection. Gates Ventures also co-founded the ADDF Diagnostics Accelerator ($150 million invested since 2018, with an additional $50 million committed for Phase 3) and co-leads the European ACCESS-AD consortium (€38 million over five years), which integrates brain imaging, blood-based biomarkers, digital monitoring, and AI-driven decision support. The Gates Notes blog is maintained as Bill Gates' content platform.

The firm's business model is that of a private investment office: it does not sell products or services, does not publicly disclose pricing, and has no disclosed revenue. It manages Bill Gates' personal wealth and coordinates multi-stakeholder consortia that blend philanthropy, venture investment, and research infrastructure. Capital sources include Gates' personal wealth, the planned $200 billion Gates Foundation deployment between 2025 and 2045, and co-funding from pharmaceutical and academic partners. The firm previously funded BENlabs (a product placement agency founded by Gates in 1989) but withdrew that funding in January 2026 after BENlabs failed to reach independent profitability.

Name

Gates Ventures

Website

https://www.gatesnotes.com/

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

51–100 employees

Short description

Gates Ventures is the private investment office of Bill Gates, managing his personal investments outside the Gates Foundation. It coordinates global health and Alzheimer's research initiatives, including the AD Workbench data platform, the SpeechDx speech-AI study, and the ACCESS-AD European consortium.

Ownership category

akta.pro rank

Product category

Venture Capital and Private Investment

NAICS

Funds, Trusts, and Other Financial Vehicles (525)

SIC

Investment Advice (6282)

akta.pro primary industry

Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)

akta.pro secondary industry

Corporate Foundations & CSR Grantmaking (BPAGAKAC)

Keywords

• Venture capital firm
• Private investment office
• Alzheimer's research funding
• Global health philanthropy
• Science and technology ventures

Headquarters

HQ city

Kirkland

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Marketing channels1 record

Core offering

Gates Ventures is Bill Gates' personal private venture and investment office that manages his investments, co-founds research initiatives, and coordinates scientific programs outside of the Gates Foundation. It deploys long-term capital through vehicles such as the Diagnostics Accelerator and supports technology platforms including the AD Workbench data sharing environment and the SpeechDx observational study. Its core output is high-impact convening and funding of breakthrough science and technology rather than commercial product sales.

Product overview

Gates Ventures operates primarily as an investment and initiative coordination vehicle rather than a product company. The main technology platform under its umbrella is the AD Workbench, developed through the Alzheimer's Disease Data Initiative, which provides a cloud-based research environment connecting dementia research datasets. Additionally, Gates Ventures supports the SpeechDx initiative for AI-driven Alzheimer's detection through speech analysis. The company also maintains Gates Notes, a content platform for Bill Gates's writings on various topics including technology and global health initiatives.

Differentiator

Problem solved

Functional benefit

Products and services

• AD Workbench A free cloud-based research environment and data sharing platform developed by the Alzheimer's Disease Data Initiative (ADDI) that connects hundreds of dementia research datasets for global scientific collaboration. It is intended for dementia and Alzheimer's researchers worldwide.
• SpeechDx A multinational observational study generating a gold-standard longitudinal dataset to train and validate AI-driven speech analysis tools for earlier Alzheimer's detection and risk assessment. The dataset has been licensed by Siemens Healthineers and Callyope. Intended for Alzheimer's researchers and diagnostic AI developers.
• Gates Notes Bill Gates' personal blog and newsletter platform where he writes about technology, global health, education, energy, climate change, and Alzheimer's research. Open to the general public as a content subscription.

Segments1 record

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature1 record

Partnerships

Five partnerships are on record, tiered secondary and core.

• Global Alzheimer's Platform Foundation (GAP)secondaryStrategic or Co-development Partner · 18 May 2026GAP's Bio-Hermes-002 observational study stores data on the AD Workbench platform from Gates Ventures' Alzheimer's Disease Data Initiative. Sanofi joined as the newest pharmaceutical partner, joining existing partners Biogen, Eli Lilly, and Roche in evaluating blood-based and digital biomarkers alongside imaging.
• Alzheimer's Drug Discovery Foundation (ADDF) Diagnostics AcceleratorcoreStrategic or Co-development Partner · 18 March 2026Gates Ventures co-founded the Diagnostics Accelerator initiative with the ADDF and Leonard A. Lauder. The initiative has invested $150 million since 2018 to advance Alzheimer's diagnostics, with an additional $50 million committed for Phase 3 focusing on tau pathology, multi-marker panels, and digital biomarkers.
• ACCESS-AD ConsortiumcoreStrategic or Co-development Partner · 15 January 2026European initiative co-led by King's College London, Amsterdam UMC, Siemens Healthineers, and Gates Ventures with an initial budget of over €38 million over five years. The consortium aims to accelerate Alzheimer's disease diagnosis and treatment by integrating brain imaging, blood-based biomarkers, digital monitoring tools, and AI-driven decision support into unified patient pathways across Europe.
• Alzheimer's Disease Data Initiative (ADDI)coreStrategic or Co-development Partner · 19 August 2025Gates Ventures supports the Alzheimer's Disease Data Initiative, which developed the AD Workbench platform. ADDI launched the Alzheimer's Insights AI Prize competition offering a $1 million prize for agentic AI solutions to accelerate dementia research. The prize pool was doubled to $2 million due to strong entries.
• SpeechDx Study PartnerscoreStrategic or Co-development PartnerSpeechDx is a three-year multinational observational study generating a gold-standard longitudinal dataset to train AI-driven speech analysis tools for Alzheimer's detection. Gates Ventures backs this initiative alongside the $150 million Diagnostics Accelerator. The dataset has been licensed by Siemens Healthineers and Callyope.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Vulcan Capital: Paul Allen's personal investment vehicle managing his estate, philanthropic, and venture activities across technology, science, and impact themes. Directly comparable as another tech billionaire's personal investment office with diversified science/tech exposure and similar scale of patient capital.
• Emerson Collective: Laurene Powell Jobs' investment and philanthropy organization funding education, immigration, climate, and health initiatives. Comparable as a founder-led family office combining venture investing with philanthropic initiative coordination across focused verticals.
• Schmidt Futures: Eric and Wendy Schmidt's philanthropic and investment vehicle funding science, technology, and society initiatives. Comparable in structure as a tech founder's personal office deploying substantial capital into science research and technology bets outside a traditional VC fund structure.
• Bezos Expeditions: Jeff Bezos' personal investment office making concentrated bets across space (Blue Origin), media (Washington Post), climate, and biotech. Comparable as another ultra-high-net-worth founder's personal investment vehicle with thematic focus areas.
• Ballmer Group: Steve Ballmer's philanthropic and investment vehicle focused on economic mobility for children and families in the US. Comparable as a Microsoft alumnus-led personal office combining philanthropic deployment with mission-driven investing.

Broad incumbents

• Breakthrough Energy Ventures: Bill Gates-cofounded climate-focused VC fund backed by a coalition of billionaire LPs (Bezos, Branson, Gates, etc.). Directly comparable as another Gates-anchored investment vehicle, focused specifically on climate/energy breakthrough technologies at venture stage.
• ARCH Venture Partners: Long-tenured science-focused VC firm investing in early-stage biotech, health, and deep tech. Comparable in its emphasis on breakthrough science investing and long-horizon patient capital, though structured as a traditional fund rather than a personal office.
• Khosla Ventures: Vinod Khosla's venture firm taking bold, science-heavy bets across health, energy, and frontier tech. Comparable as a founder-led, conviction-driven VC with thematic concentration and willingness to fund contrarian, breakthrough-science bets over multiple cycles.

Others

• Alzheimer's Drug Discovery Foundation (ADDF): Co-founding partner with Gates Ventures on the Diagnostics Accelerator. Comparable as a key ecosystem partner funding and coordinating Alzheimer's diagnostics R&D — directly collaborating on Gates Ventures' flagship health initiative.
• Alzheimer's Disease Data Initiative (ADDI): Nonprofit organization backed by Gates Ventures that developed and operates the AD Workbench platform. Directly comparable as Gates Ventures' principal data-platform partner and initiative vehicle for global dementia research collaboration.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments6 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gates Ventures